Menu
Chordate has spent more than ten years developing Kinetic Oscillation Stimulation, Ozilia® Migraine, a technique for treating rhinitis and migraine. We have a patent on Ozilia® Migraine in the EU and the US, among other countries.
Both nasal congestion and migraines affect a large number of people globally. The treatment for nasal congestion is available in the Nordic countries, the EU, Israel and Saudi Arabia. We are currently conducting important clinical studies in both of these areas of therapy.
Ozilia® Migraine can be an almost side-effect free alternative to medication for migraines. It is fast, pain-free and cheap. The method is based on so-called neuromodulation, which is an area that is growing rapidly within several medical fields. Our goal is to be an important contributor to this development.
Our investors see the enormous potential that exists in a treatment that is cheap, fast and has minimal side effects for migraine and rhinitis.
We are a Swedish medical technology company listed on Nasdaq First North Growth Market.
Chordate has spent more than 10 years developing the treatment Ozilia®, which is based on Kinetic Oscillation Stimulation, a technique for treating chronic migraine and chronic rhinitis. We have a patent on Ozilia® in the EU and the United States, as well as many other countries.
We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia®, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH).
The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.